This year, adalimumab is the target of interest. This anti-inflammatory drug is used in the treatment of rheumatoid arthritis, among others. Monitoring the levels of adalimumab in blood is essential in bringing such treatments to a successful ending. However, measuring these levels is typically done in a laboratory which is expensive and time-consuming. Biosensors on the other hand offer a quick and user-friendly solution, resulting in better therapeutic decisions and saving unnecessary costs.